Molnupiravir-COVID antidrug launched in India

COVID antidrug Molnupiravir was launched on Monday at Rs 1,399 for a 5-day course for mild to moderate infection.

The COVID cases in the country have taken the peak yet again, an expert panel of Central Drug Standard Control Organisation had recently approved anti drug Molnupiravir for restricted use.

Molnupiravir, developed by MSD and Ridgeback Biotherapeutics, is also the first oral anti-Covid pill approved by UK's drug regulator.

The US Food and Drug Administration (USFDA) has also cleared Molnupiravir for the treatment of mild-to-moderate Covid-19 in adults, and for those who are at a high risk to severe disease.